Noxopharm Ltd has released a press release.
Appendix 4D and Half Year 2022 Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- December 2021 Quarterly Activities Report and Appendix 4C
- Noxopharm Receives A$5.865M R & D Tax Rebate
- Noxopharm Announces Leadership Transition
- Noxopharm DARRT-2 Cancer Trial Update
- Noxopharm In-Licenses Novel RNA Technology From Hudson Institute of Medical Research
Later from Noxopharm
- First Patient Treated in CEP-2 Sarcoma Trial
- Orphan Drug Designation Granted to Noxopharm by US FDA
- FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment
- March 2022 Quarterly Activities Report and Appendix 4C
- June 2022 Quarterly Activities Report and Appendix 4C
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm